AUPH vs. BMY
Compare and contrast key facts about Aurinia Pharmaceuticals Inc. (AUPH) and Bristol-Myers Squibb Company (BMY).
Performance
AUPH vs. BMY - Performance Comparison
Loading graphics...
AUPH vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AUPH Aurinia Pharmaceuticals Inc. | -3.01% | 77.62% | -0.11% | 108.10% | -81.11% | 65.37% | -31.74% | 197.07% | 50.55% | 115.71% |
BMY Bristol-Myers Squibb Company | 15.79% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Fundamentals
AUPH:
$2.15B
BMY:
$125.99B
AUPH:
$2.06
BMY:
$3.46
AUPH:
7.50
BMY:
17.84
AUPH:
0.00
BMY:
1.02
AUPH:
7.61
BMY:
2.61
AUPH:
3.69
BMY:
2.26
AUPH:
$283.06M
BMY:
$48.19B
AUPH:
$250.39M
BMY:
$30.43B
AUPH:
$109.83M
BMY:
$13.82B
Returns By Period
In the year-to-date period, AUPH achieves a -3.01% return, which is significantly lower than BMY's 15.79% return. Over the past 10 years, AUPH has outperformed BMY with an annualized return of 18.02%, while BMY has yielded a comparatively lower 2.90% annualized return.
AUPH
- 1D
- 4.39%
- 1M
- 8.87%
- YTD
- -3.01%
- 6M
- 35.70%
- 1Y
- 92.17%
- 3Y*
- 12.17%
- 5Y*
- 3.32%
- 10Y*
- 18.02%
BMY
- 1D
- 1.78%
- 1M
- -0.98%
- YTD
- 15.79%
- 6M
- 33.50%
- 1Y
- 8.90%
- 3Y*
- 0.70%
- 5Y*
- 3.49%
- 10Y*
- 2.90%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AUPH vs. BMY — Risk / Return Rank
AUPH
BMY
AUPH vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| AUPH | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.04 | 0.31 | +1.73 |
Sortino ratioReturn per unit of downside risk | 2.66 | 0.64 | +2.02 |
Omega ratioGain probability vs. loss probability | 1.38 | 1.08 | +0.30 |
Calmar ratioReturn relative to maximum drawdown | 5.81 | 0.25 | +5.56 |
Martin ratioReturn relative to average drawdown | 12.66 | 0.39 | +12.26 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| AUPH | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.04 | 0.31 | +1.73 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.05 | 0.15 | -0.10 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.24 | 0.12 | +0.13 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.17 | 0.35 | -0.18 |
Correlation
The correlation between AUPH and BMY is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
AUPH vs. BMY - Dividend Comparison
AUPH has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.03%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AUPH Aurinia Pharmaceuticals Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.03% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Drawdowns
AUPH vs. BMY - Drawdown Comparison
The maximum AUPH drawdown since its inception was -87.58%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for AUPH and BMY.
Loading graphics...
Drawdown Indicators
| AUPH | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.58% | -72.03% | -15.55% |
Max Drawdown (1Y)Largest decline over 1 year | -15.91% | -25.79% | +9.88% |
Max Drawdown (5Y)Largest decline over 5 years | -87.58% | -47.67% | -39.91% |
Max Drawdown (10Y)Largest decline over 10 years | -87.58% | -47.67% | -39.91% |
Current DrawdownCurrent decline from peak | -53.23% | -12.07% | -41.16% |
Average DrawdownAverage peak-to-trough decline | -49.17% | -22.40% | -26.77% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.30% | 16.06% | -8.76% |
Volatility
AUPH vs. BMY - Volatility Comparison
Aurinia Pharmaceuticals Inc. (AUPH) has a higher volatility of 13.51% compared to Bristol-Myers Squibb Company (BMY) at 6.68%. This indicates that AUPH's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| AUPH | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.51% | 6.68% | +6.83% |
Volatility (6M)Calculated over the trailing 6-month period | 26.87% | 19.39% | +7.48% |
Volatility (1Y)Calculated over the trailing 1-year period | 45.40% | 28.61% | +16.79% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 68.71% | 23.68% | +45.03% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 74.42% | 25.08% | +49.34% |
Financials
AUPH vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Aurinia Pharmaceuticals Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities